You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨麗珠醫藥(01513.HK)高開6.34% 重組蛋白新冠疫苗序貫加強後對奧密克戎有良好保護力
格隆匯2月17日丨麗珠醫藥(01513.HK)高開6.34%,報30.2港元,總市值283億港元。麗珠醫藥昨晚公吿,公司控股附屬公司麗珠單抗與中科院生物物理研究所合作研發的“重組新型冠狀病毒融合蛋白疫苗”(簡稱“V-01”)已完成序貫加強Ⅲ期臨牀試驗的中期主數據分析,並獲得了關鍵性數據。此次試驗表明V-01序貫加強對於Omicron感染導致的COVID-19可產生良好保護力。同時,未發現有值得關注的安全性問題。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account